SCHEMBL26100249

SCHEMBL26100249

COc1cc2c(-c3ccc(NC(=O)Cc4ccc(C(F)(F)F)cc4)cc3)ncnc2cc1OCc1cccnc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PDK1 Q15118 1/20 0.50
▸ KDR P35968 5/20 0.49
▸ FLT1 P17948 1/20 0.49
▸ EPHA2 P29317 1/20 0.49
▸ EPHB4 P54760 1/20 0.49
▸ KIT P10721 2/20 0.48
▸ PDGFRB P09619 8/20 0.47
▸ CSF1R P07333 3/20 0.47
▸ RET P07949 2/20 0.47
▸ PDGFRA P16234 1/20 0.47
▸ DDR1 Q08345 1/20 0.47
▸ FLT4 P35916 7/20 0.47
▸ FLT3 P36888 5/20 0.47
▸ BRAF P15056 2/20 0.46
▸ KIF5B P33176 1/20 0.46
▸ RAF1 P04049 1/20 0.46
▸ HDAC1 Q13547 1/20 0.46
▸ EGFR P00533 1/20 0.45
▸ MET P08581 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30393909 1.00 PDK1 (0.50) PDK1KDRFLT1EPHA2EPHB4
SCHEMBL30394324 1.00 PDK1 (0.50) PDK1KDRFLT1EPHA2EPHB4
SCHEMBL26536178 1.00 PDK1 (0.50) PDK1KDRFLT1EPHA2EPHB4
SCHEMBL26102818 0.91 EGFR (0.54) KDRKITPDGFRBCSF1RRET
SCHEMBL30394611 0.86 KDR (0.54) KDRKITPDGFRBCSF1RRET
SCHEMBL29238215 0.86 KDR (0.54) KDRKITPDGFRBCSF1RRET
SCHEMBL26102182 0.85 KDR (0.51) KDRFLT1KITPDGFRBCSF1R
SCHEMBL26102366 0.85 KDR (0.51) KDRFLT1KITPDGFRBCSF1R
SCHEMBL26098922 0.84 KDR (0.52) KDRKITPDGFRBCSF1RRET
SCHEMBL29238333 0.83 KDR (0.49) KDRKITPDGFRBCSF1RRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF VORONOI INC (KR) 2026-05-21 — — US claimed
EP-4424675-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF Voronoi Inc. (KR) 2024-09-04 — — EP claimed
CN-118201909-A Quinazoline derivative compound and use thereof 株式会社沃若诺伊 2024-06-14 — — CN claimed
WO-2023075529-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF 보로노이바이오 주식회사 2023-05-04 — — WO disclosed
WO-2023075529-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF 보로노이바이오 주식회사 2023-05-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF PDGFRA, KIT, PDGFRB PDK1 711/4885KDR 5/4885FLT1 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback